Alport Syndrome Market Research Report By Genetic Mutations (COL4A3 Mutations, COL4A4 Mutations, COL4A5 Mutations), By Severity (Alport Syndrome with Nephropathy, Alport Syndrome without Nephropathy, Ocular Alport Syndrome), By Treatment Type (Medications, Nephrectomy, Kidney Transplant), By Patient Population (Pediatric Patients, Adult Patients), By End-user (Hospitals, Clinics, Research Centers) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Forecast to 2032

Alport Syndrome Market Overview

As per MRFR analysis, the Alport syndrome market size was estimated at 2.01 (USD Billion) in 2022. The Alport syndrome market industry is expected to grow from 2.12(USD Billion) in 2023 to 3.5 (USD Billion) by 2032. The Alport syndrome market CAGR (growth rate) is expected to be around 5.71% during the forecast period (2024 - 2032).

Key Alport Syndrome Market Trends Highlighted

The Alport Syndrome Market is expected to witness significant growth in the coming years due to increasing awareness and advancements in genetic testing and therapies. The market is driven by factors such as rising prevalence of the disease, growing demand for early diagnosis and treatment, and increasing research and development activities.

The rising prevalence of Alport syndrome, particularly in certain regions, is a major factor driving market growth. Early diagnosis and treatment are crucial for managing the condition, leading to an increasing demand for genetic testing and novel therapies. Furthermore, the advent of gene therapy and other advanced treatments is expected to create new opportunities for market growth.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Alport Syndrome Market Drivers

Increasing Prevalence of Alport Syndrome

Alport syndrome is a rare genetic disease that affects the kidneys, eyes, and ears. The disease is caused by mutations in the genes encoding several proteins involved in the filtration process in the kidney. The increasing spread of Alport syndrome is a major factor driving the global Alport syndrome market.

There are several reasons for that such as the increasing number of people affected with kidney diseases, growing awareness for Alport syndrome, and new medication and diagnostic methods. The Alport Syndrome Market is projected to continue its growth in the upcoming years, driven by the increasing spread of the syndrome.

Rising Demand for Alport Syndrome Therapies

One of the factors that drive the demand for Alport syndrome market is the increasing number of the population with the disease. Currently, there is no cure for the disease and the treatment options are limited.

However, the rapid expansion of new therapies that can lessen the progression of the disease and enhance the ability to live higher quality life advance the global Alport syndrome market. It is expected that the Alport Syndrome Market will continue to expand in the next years due to the increasing demand for new therapies.

Government Initiatives to Support Alport Syndrome Research

Government initiatives to support Alport syndrome research provide another major driver of the global Alport syndrome market. These initiatives have enabled researchers to come up with new diagnostic methods and forms of treatment on time.

Moreover, government initiatives on the same have enabled people to have increased awareness of the dreadful condition. In the next few the years, the Alport Syndrome Market will keep growing to higher levels as the government continues to increase funds to support research.

Alport Syndrome Market Segment Insights

Alport Syndrome Market Genetic Mutations Insights

The Alport Syndrome Market segmentation by genetic mutations includes COL4A3 mutations, COL4A4 mutations, and COL4A5 mutations. These mutations affect the production or the structure of type IV collagen that is found at the glomerular basement membrane of the kidney.

COL4A3 Mutations: They constitute about 80% of the cases of Alport syndrome. COL4A3 Mutations are almost exclusive for the alpha-3 chain of type IV collagen. These types result in structural defects of the GBM leading to progressive kidney damage and deafness. The frequency of COL4A3 Mutations varies among different populations in which its frequency is higher in Finland and Italy.

COL4A4 Mutations: These types account for about 15% of cases of Alport syndrome. They affect the alpha-4 chain of type IV collagen, and like COL4A3 mutations they influence the structure and the function of the GBM leading to kidney disease and deafness. The more frequent regions in which COL4A4 Mutations is higher than it is in Japan and the United States.

COL4A5 Mutations: These types are found in about 5% of the cases of Alport syndrome. They affect the alpha-5 chain of type IV collagen. They are associated with a milder form of the syndromes in which the affected individual does not progress to renal failure, and they are presented only with isolated hematuria and the renal damage is very slow.

The Alport Syndrome Market revenue will be US$ 2.45 billion in 2024. This huge market growth will be due to the increase in its prevalence, the increased awareness of the disease and the advances in its therapeutic approaches.

This market is categorized according to the type of genetic mutations in which COL4A3 mutations is the biggest section of the market. Knowledge about the molecular changes of Alport syndrome is very important for the accurate diagnosis, prognosis and the development of new therapeutic approaches.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Alport Syndrome Market Severity Insights

The Alport Syndrome Market has been segmented based on severity into Alport syndrome with nephropathy, Alport syndrome without nephropathy, and ocular Alport syndrome; among these, the Alport Syndrome with Nephropathy segment accounted for the largest share in 2023 and is expected to record significant growth throughout the forecast period.

The growth of this segment can be attributed to the increasing prevalence of Alport Syndrome with Nephropathy; this is the most severe form of the disease and damages the kidneys. In addition, the growing demand for the early diagnosis and treatment of Alport Syndrome with Nephropathy is aiding the growth of this segment.

The Alport syndrome without nephropathy segment is expected to grow at a steady rate throughout the forecast period. This segment includes the patients who have the disease, but do not develop kidney disease. The growth of the Ocular Alport Syndrome segment is expected to be moderate over the forecast period. This segment includes the patients who have Alport Syndrome, which primarily affects the eyes.

Alport Syndrome Market Treatment Type Insights

The treatment type segment of the Alport Syndrome Market is categorized into medications, nephrectomy, and kidney transplant. Medications accounted for the largest revenue share in 2023, and it is expected to maintain its dominance throughout the forecast period. The growth of this segment can be attributed to the increasing prevalence of Alport syndrome and the availability of various medications to manage the condition.

Nephrectomy, the surgical removal of a kidney, is another common treatment option for Alport syndrome. Kidney Transplant is the most invasive and expensive treatment option, but it offers the best chance of long-term survival.

The Alport Syndrome Market for medications is expected to reach USD 1.2 billion by 2024, growing at a CAGR of 5.5%. The market for nephrectomy is expected to reach USD 0.4 billion by 2024, growing at a CAGR of 4.8%. The kidney transplant segment is expected to reach USD 0.6 billion by 2024, growing at a CAGR of 6.0%.

Alport Syndrome Market Patient Population Insights

The Alport Syndrome Market is segmented by patient population into pediatric patients and adult patients. In 2023, the pediatric patients segment accounted for a larger share of the market, due to the higher prevalence of Alport syndrome in children.

However, the adult patients’ segment is expected to grow at a faster CAGR during the forecast period, due to the increasing incidence of Alport Syndrome in adults and the rising awareness of the condition.

By 2032, the adult patients’ segment is expected to account for a larger share of the market. The growth of the adult patients’ segment is expected to be driven by the increasing incidence of Alport Syndrome in adults and the rising awareness of the condition.

Alport Syndrome Market End-user Insights  

The Alport Syndrome Market is segmented by end-user into hospitals, clinics, and research centers. Hospitals are expected to account for the largest share of the market in 2023, owing to the increasing number of patients diagnosed with Alport syndrome and the availability of advanced treatment facilities in hospitals.

Clinics are also expected to witness significant growth in the market, as they offer specialized care for patients with Alport syndrome. Research centers are expected to contribute to the growth of the market, as they are involved in the development of new drugs and therapies for the treatment of Alport syndrome.

Alport Syndrome Market Regional Insights

The Alport Syndrome Market revenue is expected to grow significantly over the forecast period, with a notable regional presence in North America, Europe, APAC, South America, and MEA. North America held the largest market share in 2023 and is projected to maintain its dominance throughout the forecast period.

The high prevalence of Alport syndrome and the presence of advanced healthcare infrastructure contribute to the region's growth. Europe is also a significant market for Alport syndrome treatment, with a strong focus on research and development.

The APAC region is expected to witness substantial growth due to increasing awareness about the condition and improving healthcare access. South America and MEA hold a relatively smaller market share but are projected to grow at a steady pace, driven by rising healthcare investments and government initiatives.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Alport Syndrome Market Key Players and Competitive Insights

Major players in the Alport syndrome market, such as Alexion Pharmaceuticals, Inc. and BioMarin Pharmaceutical Inc., are actively involved in developing novel therapies for Alport syndrome. These companies are investing in research and development to enhance the efficacy and safety of existing treatments, as well as to explore new therapeutic approaches. Partnerships and collaborations among industry players are also prevalent, with the aim of leveraging expertise and resources to accelerate Alport syndrome drug development.

Alexion Pharmaceuticals, Inc., a leading player in the Alport syndrome market, provides innovative therapies for rare diseases. The company's Soliris (eculizumab) is approved for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Alexion is also evaluating the potential of Soliris in Alport syndrome, with ongoing clinical trials investigating its efficacy and safety.

BioMarin Pharmaceutical Inc., another prominent player in the Alport Syndrome Market, has a robust pipeline of therapies for rare genetic diseases. The company's Vimizim (elosulfase alfa) is approved for the treatment of Morquio A syndrome, and it is also investigating the potential of this therapy in Alport syndrome. BioMarin's commitment to rare disease research and development positions it as a key player in the Alport syndrome market.

Key Companies in the Alport Syndrome Market Include:

• Alexion Pharmaceuticals Inc.


• Novartis AG


• Genentech Inc.


• BioMarin Pharmaceutical Inc.


• Apellis Pharmaceuticals Inc.


• Horizon Therapeutics plc


• Idorsia Pharmaceuticals Ltd.


• Alnylam Pharmaceuticals Inc.


• Takeda Pharmaceutical Company Limited


• Janssen Pharmaceuticals Inc.


• Chugai Pharmaceutical Co. Ltd.


• HoffmannLa Roche Ltd.


• Pfizer Inc.


• Sanofi S.A.


• Merck & Co. Inc.

Alport Syndrome Market Developments

The Alport syndrome market is expected to witness significant growth in the coming years. In 2023, the market was valued at 2.12 billion USD, and it is projected to reach 3.5 billion USD by 2032, exhibiting a CAGR of 5.71%. This growth is attributed to the rising prevalence of Alport syndrome, increasing awareness about the condition, and the development of new treatment options.

Recent developments in the market include the approval of Sparsentan, the first FDA-approved treatment for Alport Syndrome, by the US FDA in 2023. Additionally, several clinical trials are currently underway to evaluate the efficacy and safety of novel therapies for Alport syndrome. These factors are expected to drive the growth of the Alport Syndrome market in the coming years.

Alport Syndrome Market Segmentation Insights

• 
  

  Alport Syndrome Market Genetic Mutations Outlook

  
  
  
  
  • COL4A3 Mutations
  
  
  • COL4A4 Mutations
  
  
  • COL4A5 Mutations
  
  
  
  


• 
  

  Alport Syndrome Market Severity Outlook

  
  
  
  
  • Alport Syndrome with Nephropathy
  
  
  • Alport Syndrome without Nephropathy
  
  
  • Ocular Alport Syndrome
  
  
  
  


• 
  

  Alport Syndrome Market Treatment Type Outlook

  
  
  
  
  • Medications
  
  
  • Nephrectomy
  
  
  • Kidney Transplant
  
  
  
  


• 
  

  Alport Syndrome Market Patient Population Outlook

  
  
  
  
  • Pediatric Patients
  
  
  • Adult Patients
  
  
  
  


• 
  

  Alport Syndrome Market End-user Outlook

  
  
  
  
  • Hospitals
  
  
  • Clinics
  
  
  • Research Centers
  
  
  
  


• 
  

  Alport Syndrome Market Regional Outlook

  
  
  
  
  • North America
  
  
  • Europe
  
  
  • South America
  
  
  • Asia Pacific
  
  
  • Middle East and Africa